Aryeh joined the TAP Advisors Health Care group in April 2016. Prior to joining TAP, Mr. Sand was a senior banker in Mizuho’s Health Care Investment Banking group in New York, where he was an integral part of the coverage team for all of the firm’s major health care clients, including Allergan, Amgen, Biogen, Danaher, Express Scripts, Gilead, and Mallinckrodt.
Mr. Sand has extensive M&A advisory and financing expertise, and played meaningful roles in several important transactions including Actavis’ $70bn acquisition of Allergan, Actavis’ $28bn acquisition of Forest Laboratories, Mallinckrodt’s $690MM divestiture of its Nuclear Imaging Business, BWXT Medical’s JV with Global Medical Solutions, Alora Pharma’s $170 MMM acquisition of Osmotica’s legacy business, CutisPharma’s sale to NovaQuest Capital Management, ROMEG Therapeutics licensing of US rights to Gloperba to Avion Pharmaceuticals, SWK Holdings’ restructuring and sale of its interests in ABT Molecular, and Upsher-Smith Laboratories’ divestiture of its women’s health brands.
Stephen has over 20 years of experience developing transformative technologies in the financial services, government, and commercial sectors. He is an expert in applying ML and AI technologies at scale in diverse applications, from national security to customer relationship management.
At causaLens, Stephen is responsible for product strategy and growth in the banking and insurance sectors.
Prior to causaLens, Stephen held senior positions at leading deep technology companies, including roles as Chief Innovation Officer at Symphony Ayasdi AI, Solutions Director at Simility-Paypal, Solutions Director at ThreatMetrix, and Head of Products at BAE NetReveal.
Stephen holds a PhD in Astrophysics from Cambridge University.
Harry is the co-founder and CEO of Hazy, a synthetic data company helping its customers set their data free. Harry has spent his career working for and founding technology startups in the digital manufacturing and data spheres. Harry believes passionately that ethical businesses need to be equipped with usable privacy tools to protect their users and remain competitive in a world where privacy and competitive advantage are increasingly at odds with one another.
Bobbie Whiddon is presently the supervisor over the FDA imports group in Philadelphia. He has been with the FDA for almost nine years. Bobbie has acquired over 20 years of public health and environmental health experience through various positions in both government and industry.
FDA determines whether products are admissible into U.S. commerce and may refuse entry to any that violate or appear to violate any provisions of the Federal Food Drug and Cosmetic Act (FFD&C Act). Importers of products intended for introduction into U.S. interstate commerce are responsible for ensuring that the products are safe, sanitary, and labeled according to U.S. requirements. Imported products are subject to FDA inspection when offered for import at U.S. ports of entry. FDA may detain shipments of products offered for import if the shipments are found not to be in compliance with U.S. requirements. Both imported and domestically-produced foods must meet the same legal requirements in the United States.
Andreas Sonnleitner has 23 years of industry experience in the financial sector. The certified credit manager supports customers with solutions in risk management, leasing and receivables management and was already able to contribute his expertise to companies such as abcfinance and FinTecSystems in earlier years.
In 2019 Andreas joined Experian DACH as Senior Sales Manager, Finance & Payment and is primarily responsible for automotive and retail banks as well as leasing companies.
